HTG MOLECULAR DIAGNOSTICS, INC: Nasdaq/NYSE listing notice — HTG Molecular Diagnostics receives Nasdaq delisting notice due to Chapter 11 filing; trading suspended June 15

HTG MOLECULAR DIAGNOSTICS, INC

Delisting notice received June 6, 2023 from Nasdaq staff after company's Chapter 11 bankruptcy filing.
Trading of HTGM common stock suspended at open on June 15, 2023; Form 25-NSE to follow.
Nasdaq cited concerns over continued listing compliance, residual equity interest, and public interest.
Company does not intend to appeal the delisting determination.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

HTG MOLECULAR DIAGNOSTICS, INC received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

Exchange: nasdaq
Notice: delisting notice
Rules: 5101, 5110(b), IM-5101-1

Exact text from the filing

June 6, 2023, the Company received written notice (the “Delisting Notice”) from the staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, as a result of the Company's filing for protection under Chapter 11 of the U.S. Bankruptcy Code (the "Filing") and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq had determined that the Company’s common stock (the “Securities”) will be delisted from Nasdaq. Trading of the Securities will be suspended at the opening of business on June 15, 2023 and a Form 25-NSE will be filed with the Securities and

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-23-027044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.